"Enzyme Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
| Descriptor ID |
D004791
|
| MeSH Number(s) |
D27.505.519.389
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Enzyme Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Enzyme Inhibitors".
This graph shows the total number of publications written about "Enzyme Inhibitors" by people in this website by year, and whether "Enzyme Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 5 | 5 |
| 1997 | 0 | 4 | 4 |
| 1998 | 1 | 2 | 3 |
| 1999 | 1 | 3 | 4 |
| 2000 | 3 | 4 | 7 |
| 2001 | 0 | 11 | 11 |
| 2002 | 3 | 9 | 12 |
| 2003 | 1 | 9 | 10 |
| 2004 | 0 | 9 | 9 |
| 2005 | 2 | 5 | 7 |
| 2006 | 5 | 4 | 9 |
| 2007 | 3 | 9 | 12 |
| 2008 | 2 | 10 | 12 |
| 2009 | 7 | 3 | 10 |
| 2010 | 2 | 4 | 6 |
| 2011 | 2 | 4 | 6 |
| 2012 | 2 | 1 | 3 |
| 2013 | 5 | 7 | 12 |
| 2014 | 1 | 3 | 4 |
| 2015 | 3 | 4 | 7 |
| 2016 | 3 | 1 | 4 |
| 2017 | 3 | 4 | 7 |
| 2018 | 3 | 0 | 3 |
| 2019 | 5 | 2 | 7 |
| 2020 | 6 | 2 | 8 |
| 2021 | 3 | 1 | 4 |
| 2022 | 0 | 3 | 3 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Enzyme Inhibitors" by people in Profiles.
-
DHODH inhibition enhances the efficacy of immune checkpoint blockade by increasing cancer cell antigen presentation. Elife. 2024 Jul 08; 12.
-
Synthesis and biological characterization of an orally bioavailable lactate dehydrogenase-A inhibitor against pancreatic cancer. Eur J Med Chem. 2024 Sep 05; 275:116598.
-
Effect of Pevonedistat, an Investigational NEDD8-Activating Enzyme Inhibitor, on the QTc Interval in Patients With Advanced Solid Tumors. Clin Pharmacol Drug Dev. 2023 03; 12(3):257-266.
-
ENT1 blockade by CNX-774 overcomes resistance to DHODH inhibition in pancreatic cancer. Cancer Lett. 2023 01 01; 552:215981.
-
3D-QSAR and scaffold hopping based designing of benzo[d]ox-azol-2(3H)-one and 2-oxazolo[4,5-b]pyridin-2(3H)-one derivatives as selective aldehyde dehydrogenase 1A1 inhibitors: Synthesis and biological evaluation. Arch Pharm (Weinheim). 2022 Sep; 355(9):e2200108.
-
QSAR and deep learning model for virtual screening of potential inhibitors against Inosine 5' Monophosphate dehydrogenase (IMPDH) of Cryptosporidium parvum. J Mol Graph Model. 2022 03; 111:108108.
-
Pharmacological Inhibition of Inositol-Requiring Enzyme 1a RNase Activity Protects Pancreatic Beta Cell and Improves Diabetic Condition in Insulin Mutation-Induced Diabetes. Front Endocrinol (Lausanne). 2021; 12:749879.
-
Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2021 07 15; 27(14):3834-3844.
-
Kinetic, spectral, and structural studies of the slow-binding inhibition of the Escherichia coli dihydrodipicolinate synthase by 2, 4-oxo-pentanoic acid. Arch Biochem Biophys. 2021 05 15; 702:108819.
-
Crystal structures of glutathione- and inhibitor-bound human GGT1: critical interactions within the cysteinylglycine binding site. J Biol Chem. 2021 Jan-Jun; 296:100066.